Question to the Department of Health and Social Care:
To ask the Secretary of State for Health and Social Care, which medicinal products were made available on the NHS with a managed access agreement in (a) 2018-19 and (b) 2019 to date.
The National Institute for Health and Care Excellence (NICE) has recommended 11 topics for access via a Managed Access Agreement (MAA) in 2019/20 to date. In 2018/19, 12 topics were recommended via an MAA.
These topics are listed in the following table.
NICE ref | Drug | Indication | Managed access start date |
| |
2018/19 |
| ||||
TA522 | Pembrolizumab | locally advanced or metastatic urothelial cancer where cisplatin is unsuitable | 27 April 2018 |
| |
TA529 | Crizotinib | ROS1-positive advanced non-small-cell lung cancer | 31 May 2018 |
| |
TA528 | Niraparib | platinum-sensitive ovarian cancer after second response to chemotherapy | 1 June 2018 |
| |
TA540 | Pembrolizumab | Relapsed or refractory classical Hodgkin lymphoma | 25 July 2018 |
| |
TA554 | Tisagenlecleucel | relapsed or refractory B-cell acute lymphoblastic leukaemia | 16 November 2018 |
| |
TA553 | Pembrolizumab | adjuvant treatment of resected melanoma with high risk of recurrence | 19 November 2018 |
| |
TA557 | Pembrolizumab (with pemetrexed and platinum chemotherapy) | untreated metastatic non-squamous NSCLC | 21 November 2018 |
| |
TA558 | Nivolumab | adjuvant treatment of resected stage III and IV melanoma | 30 November 2018 |
| |
TA559 | Axicabtagene ciloleucel | diffuse large B-cell lymphoma and primary mediastinal B-cell lymphoma after 2 or more systemic therapies | 7 December 2018 |
| |
TA567 | Tisagenlecleucel | relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies | 1 February 2019 |
| |
TA573 | Daratumumab with bortezomib | Multiple myeloma | 12 March 2019 |
| |
TA578 | Durvalumab | NSCLC | 28 March 2019 |
| |
2019/2020 |
| ||||
TA579 | Abemaciclib with fulvestrant | HER2-negative breast cancer after endocrine therapy | 2 April 2019 | ||
TA581 | Nivolumab with ipilimumab | untreated advanced renal cell carcinoma | 5 April 2019 | ||
TA592 | Cemiplimab | cutaneous squamous cell carcinoma | 2 July 2019 | ||
TA588 | Nusinersen | Spinal Muscular Atrophy | 3 July 2019 | ||
TA593 | Ribociclib | in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative breast cancer | 17 July 2019 | ||
TA598 | Olaparib | maintenance treatment of newly diagnosed BRCA-mutated advanced ovarian, fallopian tube or peritoneal cancer, after response to first-line platinum-based chemotherapy | 26 July 2019 | ||
TA600 | Pembrolizumab with carboplatin and paclitaxel | Metastatic squamous NSCLC | 8 August 2019 | ||
TA611 | Rucaparib | maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer | 11 October 2019 | ||
TA619 | Palbociclib in combination with fulvestrant | advanced, HR+ HER2- breast cancer after endocrine therapy | 28 November 2019 | ||
TA620 | Olaparib | maintenance treatment of BRCA-mutated platinum sensitive relapsed ovarian, fallopian tube and peritoneal cancer, after response to platinum-based chemotherapy | 29 November 2019 | ||
HST12 | Cerliponase alfa | neuronal ceroid lipofuscinosis type 2 | 5 November 2019 |